[BSTC] BioSpecifics Technologies Corp


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 54.66 Change: 2.27 (4.33%)
Ext. hours: Change: 0 (0%)

chart BSTC

Refresh chart

Strongest Trends Summary For BSTC

BSTC is in the medium-term up 5% above S&P in 2 months. In the long-term up 53% in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. It provides injectable collagenase under the XIAFLEX name for the treatment of Dupuytren?s contracture and Peyronie?s disease. The company also develops XIAFLEX injectable collagenase for frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroid indications, as well as for keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. The company was founded in 1957 and is headquartered in Lynbrook, New York.

Fundamental Ratios
Shares Outstanding EPS1.63 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 111.07% Sales Growth - Q/Q20.56% P/E29.54
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA17.95% ROE18.48% ROI
Current Ratio31.82 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin55.74% Net Profit Margin36.77% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.08 M Cash From Investing Activities-2.15 M Cash From Operating Activities1.99 M Gross Profit
Net Profit2.33 M Operating Profit3.56 M Total Assets34.67 M Total Current Assets28.99 M
Total Current Liabilities910 K Total Debt Total Liabilities1000 K Total Revenue5.61 M
Technical Data
High 52 week71.62 Low 52 week41.15 Last close66.48 Last change1.96%
RSI45.58 Average true range2.41 Beta0.4 Volume22.66 K
Simple moving average 20 days1.27% Simple moving average 50 days-0.82% Simple moving average 200 days10.79%
Performance Data
Performance Week5.52% Performance Month5.11% Performance Quart3.91% Performance Half7.1%
Performance Year56.39% Performance Year-to-date9.7% Volatility daily2.39% Volatility weekly5.34%
Volatility monthly10.95% Volatility yearly37.92% Relative Volume155.17% Average Volume48.13 K
New High3.64% New Low


2019-05-23 08:01:00 | BioSpecifics Technologies Corp. Announces Authorization of up to $4 Million Stock Repurchase Program

2019-05-16 16:35:08 | ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

2019-05-14 14:36:06 | Catalyst CPRX Q1 Loss Narrows, Firdapse Off to a Good Start

2019-05-12 22:00:59 | Hedge Funds Have Never Been More Bullish On BioSpecifics Technologies Corp. BSTC

2019-05-10 08:26:47 | BioSpecifics: 1Q Earnings Snapshot

2019-05-02 14:34:06 | Zoetis ZTS Earnings Beat Estimates in Q1, Revenues Miss

2019-04-30 08:02:12 | What's in Store for BioSpecifics BSTC This Earnings Season?

2019-04-16 19:17:11 | Achaogen AKAO Files for Bankruptcy, Shares Plunge 65%

2019-04-12 09:45:01 | Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks

2019-04-09 10:29:02 | Zogenix Gets Refusal to File Letter From FDA for Seizure Drug

2019-04-09 10:06:02 | United Therapeutics Discontinues PAH Drug After Study Fails

2019-04-09 08:45:12 | 3 Reasons Why BioSpecifics BSTC Is a Great Growth Stock

2019-04-04 09:10:01 | 5 Stocks With Recent Price Strength Despite Market Volatility

2019-04-02 08:22:28 | BioSpecifics: 4Q Earnings Snapshot

2019-04-02 08:01:00 | BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-25 08:32:12 | Zacks.com featured expert Kevin Matras highlights: Darden Restaurants, Best Buy, BioSpecifics Technologies and ONEOK

2019-03-22 08:01:12 | 4 Top Stocks to Buy for Superb Earnings Growth

2019-03-20 09:00:01 | BioSpecifics BSTC Upgraded to Strong Buy: Here's What You Should Know

2019-03-18 08:01:00 | BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman

2019-03-05 16:36:09 | What's in Store for BioSpecifics BSTC This Earnings Season?

2019-02-21 11:27:06 | Is BioSpecifics Technologies Corp. NASDAQ:BSTC A Volatile Stock?

2019-02-04 07:35:00 | Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results

2019-01-28 09:32:02 | BioSpecifics BSTC Upgraded to Buy: Here's What You Should Know

2019-01-17 09:30:02 | Is BioSpecifics Technologies BSTC Stock Outpacing Its Medical Peers This Year?

2019-01-16 10:36:37 | Is BioSpecifics Technologies Corp.’s NASDAQ:BSTC Balance Sheet Strong Enough To Weather A Storm?

2019-01-11 10:32:03 | Ocular OCUL Submits an sNDA for Eye Pain Drug Dextenza

2019-01-10 11:00:04 | INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data

2019-01-10 08:43:01 | Weakness Seen in Champions Oncology CSBR Estimates: Should You Stay Away?

2019-01-09 09:45:02 | Karyopharm Files MAA for Myeloma Candidate Selinexor in EU

2019-01-07 12:42:05 | Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

2019-01-03 10:29:03 | Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study

2019-01-03 10:26:03 | Flexion Starts Phase III Enrollment on Zilretta for Hip OA

2019-01-02 09:25:02 | Portola Up as Large-Scale Andexxa Production Gets FDA Nod

2018-12-28 09:45:02 | Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis

2018-12-25 09:30:02 | Is BioSpecifics Technologies BSTC Outperforming Other Medical Stocks This Year?

2018-12-19 15:09:08 | Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds

2018-12-17 10:29:12 | Here’s What BioSpecifics Technologies Corp.’s NASDAQ:BSTC P/E Is Telling Us

2018-12-12 10:15:03 | Portola PTLA Down as CHMP Defers Review Date for Ondexxya

2018-12-11 17:44:10 | Jazz JAZZ Increases Share Buyback Authorization by $400M

2018-12-11 09:22:02 | Novan Announces Top-Line Data From Mid-Stage Molluscum Study

2018-12-11 08:40:01 | Why Tilray TLRY Could Be Positioned for a Slump

2018-12-06 08:46:01 | Should You Get Rid of Aerie Pharmaceuticals AERI Now?

2018-11-29 16:47:09 | Theravance Pipeline Strong, Plans Yupelri Launch by Year End

2018-11-28 10:20:03 | Theravance's Respiratory Disease JAK Inhibitor Enters Phase I

2018-11-28 08:15:00 | Market Trends Toward New Normal in Amarin, BioSpecifics Technologies, Cavco Industries, Iconix Brand Group, A-Mark Precious Metals, and Core-Mark Holding — Emerging Consolidated Expectations, Analyst Ratings

2018-11-27 13:26:21 | Is BioSpecifics Technologies Corp. NASDAQ:BSTC Worthy of Your Portfolio?

2018-11-21 11:15:04 | Theravance JAK Inhibitor Enters Phase II for Crohn's Disease

2018-11-21 09:58:02 | IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance

2018-11-20 16:25:39 | IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses

2018-11-20 08:45:01 | Galmed Pharmaceuticals GLMD in Focus: Stock Moves 6.2% Higher